Veracyte (VCYT): Exploring Valuation After Recent Share Price Rally

Simply Wall St.11-12

Veracyte (VCYT) has been attracting attention as its stock climbed nearly 22% over the past month. Investors are taking note of the company’s momentum, especially as market sentiment favors innovative...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582439437?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-11-12 02:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582439437","market":"sg","top_or_hot":-1,"title":"Veracyte (VCYT): Exploring Valuation After Recent Share Price Rally","media":"Simply Wall St.","content":"<div>\n<p>Veracyte (VCYT) has been attracting attention as its stock climbed nearly 22% over the past month. Investors are taking note of the company’s momentum, especially as market sentiment favors innovative...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracyte-vcyt-exploring-valuation-after-recent-share-price-r\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veracyte (VCYT): Exploring Valuation After Recent Share Price Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeracyte (VCYT): Exploring Valuation After Recent Share Price Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-12 02:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracyte-vcyt-exploring-valuation-after-recent-share-price-r><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Veracyte (VCYT) has been attracting attention as its stock climbed nearly 22% over the past month. Investors are taking note of the company’s momentum, especially as market sentiment favors innovative...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracyte-vcyt-exploring-valuation-after-recent-share-price-r\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracyte-vcyt-exploring-valuation-after-recent-share-price-r","article_id":"2582439437","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracyte-vcyt-exploring-valuation-after-recent-share-price-r","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582439437","pubTimestamp":1762885413,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Veracyte (VCYT) has been attracting attention as its stock climbed nearly 22% over the past month. Investors are taking note of the company’s momentum, especially as market sentiment favors innovative players in the diagnostics space.\nSee our latest analysis for Veracyte.\nVeracyte's momentum this month builds on a sharp recovery, with a 47.2% share price return in the past 90 days. This stands out against a more modest 8.9% total shareholder return over the past year. It appears that...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VCYT":"Veracyte Inc","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"Veracyte(VCYT)：近期股价上涨后探索估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1.5,"DCF":1},"content_text":"Veracyte (VCYT) has been attracting attention as its stock climbed nearly 22% over the past month. Investors are taking note of the company’s momentum, especially as market sentiment favors innovative players in the diagnostics space. See our latest analysis for Veracyte. Veracyte's momentum this month builds on a sharp recovery, with a 47.2% share price return in the past 90 days. This stands out against a more modest 8.9% total shareholder return over the past year. It appears that investors are growing increasingly optimistic about the company's growth prospects as recent results and renewed interest in diagnostics spark fresh demand for the stock. If Veracyte’s breakout run has you curious, this is a great time to discover See the full list for free. Yet with shares rallying so sharply, the key question is whether the recent gains reflect fresh upside still to come, or if the market has already priced in Veracyte’s renewed growth outlook, leaving less room for a true bargain. AdvertisementMost Popular Narrative: 3% Overvalued While Veracyte's last close of $42.35 sits just above the current fair value estimate of $41.10, market optimism is still high. The latest narrative lays out the growth runway and some of the bold underlying assumptions shaping this outlook.  Pipeline momentum, with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months, positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (for example, MRD in bladder cancer, Prosigna for breast cancer), and significantly expand addressable markets. All of this supports long-term topline acceleration.  Read the complete narrative. Want the real story behind these pipeline projections? There is a crucial financial leap embedded in these assumptions. The future numbers this narrative expects could challenge even the most bullish estimates. If you want to know which forecasts are fueling that premium, dig into the full calculation that powers this valuation. Result: Fair Value of $41.10 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are still clear risks. For example, Veracyte’s heavy reliance on its core products and potential regulatory challenges could disrupt this bullish narrative. Find out about the key risks to this Veracyte narrative. Another View: Market Multiples Paint a Different Picture While the earlier valuation set fair value just below the current share price, a look at market multiples tells a more sobering story. Veracyte is trading at a price-to-earnings ratio of 110.4x, much higher than both the biotech industry average of 17x and its peer group at 66.2x. Even compared to a fair ratio of 27.8x, the gap is stark, implying the stock carries significant valuation risk if these lofty expectations are not met. Do these stretched multiples signal growing optimism, or raise red flags about downside? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:VCYT PE Ratio as at Nov 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Veracyte for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 871 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Veracyte Narrative If you see things differently or want to dive into the numbers yourself, you can shape your own Veracyte story in just a few minutes. Do it your way A great starting point for your Veracyte research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? Don’t let the best opportunities pass you by. Uncover exciting stocks matched to your interests with these tailored screeners from Simply Wall Street:  Spot fast-growing companies at the forefront of AI by checking out these 24 AI penny stocks, which are shaking up entire industries with intelligent automation. Unlock potential deals when you search through these 871 undervalued stocks based on cash flows, where high-quality, attractively priced stocks may be flying under the radar. Catch tomorrow’s market leaders early as you browse these 3572 penny stocks with strong financials, tapping into emerging trends before the mainstream catches on.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582439437","isCrawlerRequest":true}